HER2-Negative Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
HER2-Negative Metastatic Breast Cancer Market Outlook
Thelansis’s “HER2-Negative Metastatic
Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential HER2-Negative Metastatic Breast
Cancer treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
HER2-Negative Metastatic Breast Cancer
Overview
Breast
cancer stands as the most prevalent affliction among women globally, exerting a
significant toll on mortality rates. HER2-negative breast cancer encompasses
various subtypes, including normal-like breast cancer, luminal A, partial
luminal B, and basal-like varieties. Potential inhibitors for treating
HER2-negative breast cancer include PI3K inhibitors, AKT inhibitors, and mTOR
inhibitors, which effectively suppress the PI3K/AKT signaling pathway.
Additionally, small-molecule tyrosine kinase inhibitors hinder angiogenesis,
while CDK inhibitors, aurora kinase inhibitors, and HDAC inhibitors disrupt the
cell cycle. Moreover, drugs targeting breast cancer stem cells have garnered
attention, offering innovative strategies for combating HER2-negative breast
cancer. The PI3K pathway can be roughly categorized into type I, II, and III,
with type I further divided into IA and IB. At the heart of the PI3K/AKT
pathway, AKT is regulated by diverse upstream signaling proteins, orchestrating
gene transcription, protein synthesis, and cell survival and proliferation
through various downstream pathways.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment